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Abstract: 
Atypical Hemolytic Uremic Syndrome (aHUS) is a serious hematologic disorder with 
high mortality if left untreated. A comprehensive literature review revealed only two cases of 
aHUS post heart transplantation.  In both cases the disease developed after induction of 
calcineurin inhibitor therapy. We report a case of immediate post heart transplantation aHUS, 
manifested before the induction of, and therefore not associated with, calcineurin inhibitors.  
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Patient Profile 
IRB permission was obtained to report this interesting clinical case. 
A 70-year-old female with familial end stage cardiomyopathy underwent a Heart 
Mate II (Thoratec, Pleasanton, Ca) Left Ventricular Assist Device (LVAD) placement and a 
year later she underwent orthotopic heart transplantation and LVAD explantation. Prior to 
surgery, the laboratory evaluation revealed the following: platelet count 139,000/cu mm, 
hemoglobin 9.2 gm/dl and creatinine 0.5 mg/dl. She received preoperatively mycophenolate 
mofetil and in the operating room a dose of steroids. The first postoperative day the platelet 
count was 135,000/cu mm and creatinine 1.1mg/dl. The second postoperative day severe 
thrombocytopenia was noted (22,000/cu mm) and the creatinine was 2.0 gm/dl with 
associated hyperkalemia (6.2 mmol/lt).  By the third postoperative day the platelet count did 
not improve (although platelet transfusion was administered for mediastinal bleeding) and she 
became anuric, with a creatinine level of 3.1 mg/dl and anemic (nadir hemoglobin level of 6.3 
mg/dl).  Further studies revealed an LDH of 1,460 U/l, haptoglobin level of less than 6 mg/dl 
and numerous schistocytes on the peripheral smear, consistent with microangiopathic 
hemolytic anemia (graph 1).  Shiga toxin/EHEC test was negative and the patient did not have 
gastrointestinal related symptoms. After ruling out drug-induced thrombocytopenia (no 
antibodies against platelet factor 4, confirmed by serotonin release assay), disseminated 
intravascular coagulation, or other confounding possible causes, atypical HUS was highly 
suspected and plasma exchange therapy was initiated, in addition to continuous venous-
venous hemofiltration. Thrombotic Thrombocytopenic Purpura (TTP) was excluded by a 
mildly reduced (>5%) ADAMTS 13 (a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13) activity.  At that point, mycophenolate and 
steroids were given as per our post heart transplant protocol, however; tacrolimus was held 
until post-operative day eight due to severely impaired renal function. An endomyocardial 
biopsy was performed on postoperative day thirteen and demonstrated grade 3R rejection.  
There was no evidence for humoral rejection.  Since the patient started to show signs of 
recovery, she was treated with four doses of thymoglobulin.  A repeat endomyocardial biopsy 
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on postoperative day twenty one demonstrated grade 0R rejection with Quilty effect. There 
was strong consideration to administer eculizumab therapy as a definitive treatment of 
complement mediated HUS, but in the setting of clinical improvement with plasma exchange 
this was never initiated. The patient was able to extubate on the eighth postoperative day. The 
patient received a total of twenty plasma exchange therapies and she was discharged in good 
clinical condition, with complete recovery of her renal function and normal hematologic 
values, after thirty three days of hospitalization. 
 
Discussion 
Hemolytic Uremic Syndrome (HUS) is characterized by hemolytic anemia, 
thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the 
kidney and other organs. Typical HUS is triggered by infectious agents such as strains of 
E.Coli that produce powerful Shiga-like exotoxins, whereas atypical HUS can be genetic or 
acquired, and related to Shiga-like exotoxin. Atypical HUS has a poor prognosis, with death 
rates as high as 25% and progression to end-stage renal disease in many of these patients [3].  
The association between HUS and calcineurin inhibitors therapy post solid organ 
transplantation including heart transplantation has been reported previously in literature [1, 2].  
Interestingly, in our case the syndrome was manifested before initiation of tacrolimus therapy. 
The main triggering mechanism seems to be related to endothelial dysfunction. 
Research has linked aHUS to uncontrolled activation of the complement system [3].  
Several factors that contribute to complement regulation are expressed on or bound to 
endothelium. Triggers, such as infections or a profound inflammatory state, seen during 
cardiopulmonary bypass [4], are associated with complement activation. In the presence of 
events that enhance alternative pathway activation, in genetically susceptible individuals, this 
may lead to an uncontrolled mechanism, initiating the formation of the membrane-attack 
complex and leading to complement-mediated endothelial injury [3]. Similarly, patients with 
gain-of-function mutations in complement fraction C3 or complement factor B (CFB), which 
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controls C3 convertase stabilization, may lead to chronic uncontrolled complement activation 
against the endothemium in the genetic forms of aHUS. 
The endothelial cells have anticoagulant properties, including synthesis of 
thrombomodulin, and maintance of a low synthesis of tissue factor.  Vascular endothelial 
disease or endothelial dysfunction by complement-mediated endothelial injury may result in 
decreased thrombomodulin synthesis, enhanced induction of tissue factor, and increased 
production of vWF, which synergistically promote intravascular thrombosis.  Organ 
dysfunction as a result of aHUS is triggered by the formation of platelet aggregates on the 
endothelium and dissemination of microthrombi obstructing arterioles and capillaries and 
creating shear trauma to the erythrocytes as they traverse through the microcirculation, 
resulting in fragments that are observed as schistocytes on light microscopy.  
A specific plasma metalloprotease ADAMTS13, also known as von Willebrand factor-
cleaving protease, is a zinc-containing metalloprotease, secreted from hepatocytes and is the 
responsible enzyme for the cleavage of von Willebrand factor multimers.  TTP is associated 
with severe deficiency of ADAMTS13 activity (<5%), however a mild reduction of 
ADAMTS13 function may be seen in patients with aHUS, which was verified in our patient. 
Variations of the ADAMTS13 gene (polymorphism) are partly responsible of the reduced 
ADAMTS13 function in aHUS [5]. 
Plasma exchange or plasma infusion has been used for treatment of aHUS. However, 
65% of patients with aHUS require dialysis, have permanent kidney damage, or die within 1 
year of diagnosis, likely secondary to a persistent underlying complement dysregulation and 
thrombotic microangiopathy [3,6]. Eculizumab is a monoclonal antibody that blocks the 
cleavage of C5, preventing the release of C5a, a potent anaphylatoxin and C5b, the initial 
protein of the cytotoxic membrane attach complex. Eculizumab is designed to suppress terminal 
complement activation. Clinical trials support the use of eculizumab for complement-mediated 
thrombotic microangiopathy and it is associated with substantial kidney recovery and improved 
clinical outcomes [6].  
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In conclusion, aHUS is a life threatening complication and can occur very early in post 
heart transplantation period, even in the absence of calcineurin inhibitor therapy.  Given the 
dynamic changes in laboratory parameters after heart transplantation, a high index of suspicion 
and prompt life saving intervention is paramount in management of this potentially lethal 
syndrome. 
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GRAPH 1. Laboratory data during hospitalization. 
Plasma exchange therapy started on POD 3. Tacrolimus started on POD 8. 
 

